ADMA Biologics (ADMA) reported lower-than-expected results for the first quarter. Adjusted earnings per share of 14 cents missed the Zacks Consensus Estimate of 16 cents. Revenues of $114.8 million (up 40$119 million.Consequently, the stock has plunged post the earnings announcement on May 7.Nonetheless, the company raised its annual revenue guidance for 2025 and 2026, concurrent with the quarterly results.A single quarter's results should not de ...